RxDoctor Payments DataLook up a doctor →

David Boyer, MD

Ophthalmology · Los Angeles, CANPI 1295736916

Payments from drug & device makers

$4,009,286in general payments, 2019–2025

Across 584 payments — averaging $6865.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.8M
  • Genentech, Inc.$893K
  • Boehringer Ingelheim$360K
  • Aerie Pharmaceuticals, Inc.$251K
  • Eyepoint US, Inc.$150K
  • Regeneron$93K
  • plus $498K from 42 others
$18,248in research payments, 2019–2025

Across 9 payments — averaging $2027.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$18K

What the payments were for

  • Consulting fees$368,71491%
  • Speaking & faculty fees$24,4436%
  • Travel & lodging$4,7141%
  • Food & beverage$8,0022%
  • Education$930%
  • Gifts$2630%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,009,286 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$8,005,425
Medicare patients
2,440
Services billed
91,510

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine40$10,511
LumiganBimatoprost24$6,960
SimbrinzaBrinzolamide/Brimonidine Tart35$6,955
CombiganBrimonidine Tartrate/Timolol21$6,877
ProlensaBromfenac Sodium18$6,258
Prednisolone Acetate130$5,312
Brimonidine Tartrate101$5,038
VyzultaLatanoprostene Bunod11$4,550
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol32$3,964
Loteprednol Etabonate13$2,932
Brinzolamide14$2,884
Bromfenac Sodium18$2,681
Difluprednate17$2,385
Ketorolac Tromethamine151$2,358
Latanoprost230$1,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$9,020$13,83745 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$3,394$9,19131 claims
AlconSimbrinza$1,588$6,95535 claims
Bausch & Lomb Americas Inc.Vyzulta$5,557$4,55011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →